Skip to main content

Management of melanoma, which therapeutic options?

Intervista a Axel Hauschild By 6 Dicembre 2021No Comments

Which options do we have to optimize the management of patients with melanoma, expecially if BRAF mutated? How could we correctly use target therapies and immunotherapy event in the adjuvant setting? We asked Axel Hauschild (Klinik für Dermatologie, Venerologie und Allergologie – Universitäts-Hautklinik Kiel) during the Immunotherapy & Melanoma Bridge 2021.